Global Orphan Drugs Market – Industry Analysis and Forecast (2019 – 2026) _ by Disease Type (Oncologic Diseases, Metabolic Diseases, Neurologic Diseases and Other Diseases), by Indication (Non-Hodgkins Lymphoma, Acute Myeloid Leukemia and Other) and by Geography

Global Orphan Drugs Market – Industry Analysis and Forecast (2019 – 2026) _ by Disease Type (Oncologic Diseases, Metabolic Diseases, Neurologic Diseases and Other Diseases), by Indication (Non-Hodgkins Lymphoma, Acute Myeloid Leukemia and Other) and by Geography

Market Scenario

Orphan Drugs Market is expected to reach 346.84 billion by 2026 from XX billion in 2018 at CAGR of XX.(Detailed analysis of the market CAGR is provided in the report) Orphan Drug is required to cure disease or disorder as it affects less than 1 in 2,000 people. This disease is called Orphan because their prevalence rate is very low and hence appeal to a very small patient population. Pharmaceutical industrial sector has very less interest in developing and producing these drugs because as compared to non-orphan drugs, these drugs do not guarantee healthy returns on investment.The report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis. Driving factors of Orphan Drug market is the rising prevalence of lifestyle disorder, growth in the number of private diagnostic and caring. Additionally, the rise in investment for the development of the healthcare sector by a government is anticipated to boost the market growth. Recent R&D activities related to the Orphan drug are likely to present new opportunities for the market. However, the cost of development of Orphan drugs is higher when compared with non-orphan drugs expected to restrain the market growth. Orphan drugs segment is accounted for more than 61% of the total market share by 2016. Geographically, the orphan drugs market was dominated by North America, which accounted for more than 53% of the total market share in 2016. Reasons for this growth in North America are increasing government incentives and high product demand are expected to promote market growth in the US region, which is considered to be the highest revenue-generating region in America. Key Highlights: • Orphan Drugs market analysis and forecast, in terms of value. • Comprehensive study and analysis of market drivers, restraints, and opportunities influencing the growth of the Orphan Drugs market. • Orphan Drugs market segmentation on the basis of disease type, indication and geography (country-wise) has been provided. • Orphan Drugs market strategic analysis with respect to individual growth trends, future prospects along with the contribution of various sub-market stakeholders have been considered under the scope of the study. • Orphan Drugs market analysis and forecast for five major regions namely North America, Europe, Asia Pacific, the Middle East & Africa (MEA) and Latin America along with country-wise segmentation. • Profiles of key industry players, their strategic perspective, market positioning and analysis of core competencies are further profiled. • Competitive developments, investments, strategic expansion and competitive landscape of the key players operating in the Orphan Drugs market are also profiled. Years that have been considered for the study are as follows: • Base Year – 2018 • Estimated Year – 2019 • Forecast Period – 2019 to 2026 For company profiles, 2016 has been considered as the base year. In cases, wherein information was unavailable for the base year, the years prior to it have been considered Research Methodology The market is estimated by triangulation of data points obtained from various sources and feeding them into a simulation model created individually for each market. The data points are obtained from paid and unpaid sources along with paid primary interviews with key opinion leaders (KOLs) in the market. KOLs from both, demand and supply side were considered while conducting interviews to get an unbiased idea of the market. This exercise was done at a country level to get a fair idea of the market in countries considered for this study. Later this country-specific data was accumulated to come up with regional numbers and then arrive at the global market value for Orphan Drugs Market.

Key Players in the Orphan Drugs Market Are:

• Sanofi • Glaxosmithkline Plc • Aegerion Pharmaceuticals, Inc. (Novelion Therapeutics Inc.) • Johnson & Johnson • Thermo Fisher Scientific Inc. • Novartis Ag • Abbvie Inc. • Celgene Corporation • Pfizer Inc Key Target Audience: • Orphan Drugs Market Investors• Pharmaceutical and Biotechnology Companies • Research Labs, Hospitals and Clinics • Distributors of IVD Products • Healthcare Institutions • Orphan Drugs Marketing Players

Scope of the Orphan Drugs Market Report:

research report categorizes the Orphan Drugs market based on Indication, Disease Type, and geography (region wise). Market size by value is estimated and forecasted with the revenues of leading companies operating in the Orphan Drugs market with key developments in companies and market trends

Orphan Drugs Market, By Disease Type

• Oncologic Diseases • Metabolic Diseases • Hematologic and Immunologic Diseases • Infectious Diseases • Neurologic Diseases • Other Rare Diseases

Orphan Drugs Market, By Indication

• Non-Hodgkins Lymphoma • Acute Myeloid Leukemia • Cystic Fibrosis • Glioma • Pancreatic Cancer • Ovarian Cancer • Multiple Myeloma • Duchenne Muscular Dystrophy • Graft vs. Host disease • Renal Cell Carcinoma

Orphan Drugs Market, By Geography:

• Asia Pacific • Europe • North America • Middle East & Africa • Latin America Available Customization Maximize Market Research offers customization of report and scope of the report as per the specific requirement of our client.

Table of Contents

Orphan Drugs Market

1.EXECUTIVE SUMMARY 2.RESEARCH METHODOLOGY 2.1.Market Definition 2.2.Market Scope 2.3.Data Sources 3.MARKET DYNAMICS 3.1.Market Drivers 3.2.Market Restraints 3.3.Market Opportunities 4.END-USER OVERVIEW 4.1.Value Chain Analysis 4.2.Key Trends 5.ORPHAN DRUGS MARKET, BY DISEASE TYPE (2019-2026) 5.1.Introduction 5.2. Orphan Drugs Market by Oncologic Diseases 5.2.1.Oncologic Diseases Market Overview 5.2.2.Oncologic Diseases Market Size & Forecast 5.3.Orphan Drugs Market by Metabolic Diseases 5.3.1.Metabolic Diseases Market Overview 5.3.2.Metabolic Diseases Market Size & Forecast 5.4.`Orphan Drugs Market By Hematologic and Immunologic Diseases 5.4.1.Hematologic and Immunologic Diseases Market Overview 5.4.2.Hematologic and Immunologic Diseases Market Size & Forecast 5.5.Orphan Drugs Market by Infectious Diseases 5.5.1.Infectious Diseases Market Overview 5.5.2.Infectious Diseases Market Size & Forecast 5.6.Orphan Drugs Market by Neurologic Diseases 5.6.1.Neurologic Diseases Market Overview 5.6.2.Neurologic Diseases Market Size & Forecast 5.7.Orphan drugs market by Other Rare Diseases 5.7.1.Other Rare Diseases market overview 5.7.2.Other Rare Diseases market size & forecast 6.ORPHAN DRUGS MARKET, BY INDICATION (2019-2026) 6.1.Introduction 6.2. Orphan Drugs Market by Non-Hodgkins Lymphoma 6.2.1.Non-Hodgkins Lymphoma Market Overview 6.2.2.Non-Hodgkins Lymphoma Market Size & Forecast 6.3.Orphan Drugs Market by Acute Myeloid Leukemia 6.3.1.Acute Myeloid Leukemia Market Overview 6.3.2.Acute Myeloid Leukemia Market Size & Forecast 6.4. Orphan Drugs Market by Cystic Fibrosis 6.4.1.Cystic Fibrosis Market Overview 6.4.2.Cystic Fibrosis Market Size & Forecast 6.5. Orphan Drugs Market by Glioma 6.5.1.Glioma Market Overview 6.5.2.Glioma Market Size & Forecast 6.6. Orphan Drugs Market by Pancreatic Cancer 6.6.1.Pancreatic Cancer Market Overview 6.6.2.Pancreatic Cancer Market Size & Forecast 6.7. Orphan Drugs Market by Ovarian Cancer 6.7.1.Ovarian Cancer Market Overview 6.7.2.Ovarian Cancer Market Size & Forecast 6.8.Orphan Drugs Market by Multiple Myeloma 6.8.1.Multiple Myeloma Market Overview 6.8.2.Multiple Myeloma Market Size & Forecast 6.9. Orphan Drugs Market by Duchenne Muscular Dystrophy 6.9.1Duchenne Muscular Dystrophy Market Overview 6.9.2.Duchenne Muscular Dystrophy Market Size & Forecast 6.10.Orphan Drugs Market by Graft vs. Host disease 6.10.1Graft vs. Host disease Market Overview 6.10.2.Graft vs. Host disease Market Size & Forecast 6.11.Orphan Drugs Market by Renal Cell Carcinoma 6.11.1.Renal Cell Carcinoma Market Overview 6.11.2.Renal Cell Carcinoma Market Size & Forecast 7.Orphan Drugs MARKET, BY GEOGRAPHY (2019-2026) 7.1.North America Orphan Drugs Market 7.1.1.North America Orphan Drugs Market By Decease Type 7.1.2.North America Orphan Drugs Market By Indication 7.1.3.North America Orphan Drugs Market By Region 7.1.3.1.U.S. Orphan Drugs Market 7.1.3.2.Canada Orphan Drugs Market 7.1.3.3.Mexico Orphan Drug Market 7.2.Europe Orphan Drugs Market 7.2.1.Europe Orphan Drugs Market By Decease Type 7.2.2.Europe Orphan Drugs Market By Indication 7.2.3.Europe Orphan Drugs Market By Region 7.2.3.1.Germany Orphan Drugs Market 7.2.3.2.France Orphan Drugs Market 7.2.3.3.U.K. Orphan Drugs Market 7.2.3.4. Italy Orphan Drugs Market 7.2.3.5.Spain Orphan Drugs Market 7.2.3.6.Russia Orphan Drugs Market 7.2.3.7.Rest of Europe (ROE) Orphan Drugs Market 7.3.Asia Pacific Orphan Drugs Market 7.3.1.Asia-Pacific Orphan Drugs Market By Decease Type 7.3.2.Asia-Pacific Orphan Drugs Market By Indication 7.3.3.Asia-Pacific Orphan Drugs Market By Region 7.3.3.1.Japan Orphan Drugs Market 7.3.3.2.China Orphan Drugs Market 7.3.3.3.India Orphan Drugs Market 7.3.3.4.Australia Orphan Drugs Market 7.3.3.5.South Africa Orphan Drugs Market 7.3.3.6.Taiwan Orphan Drugs Market 7.3.3.7.Rest of Asia-Pacific Orphan Drugs Market 7.4.Middle East & Africa Orphan Drugs Market 7.4.1.Middle East & Africa Orphan Drugs Market By Decease Type 7.4.2.Middle East & Africa Orphan Drugs Market By Indication 7.4.3.Middle East & Africa Orphan Drugs Market By Region 7.5.Latin America Orphan Drugs Market 7.5.1.Latin America Orphan Drugs Market By Decease Type 7.5.2.Latin America Orphan Drugs Market By Indication 7.5.3.Latin America Orphan Drugs Market By Region 7.5.3.1.Brazil Orphan Drugs Market 7.5.3.2.Rest of Latin America Orphan Drugs Market 8.MARKET COMPETITION ANALYSIS 8.1.Market Share/Positioning Analysis 8.2.Key Innovators 8.3.Company Profiles 8.3.1.Sanofi 8.3.1.1.Overview 8.3.1.2.Product Segments / End-User 8.3.1.3.Strategy 8.3.1.4.Key Developments 8.3.2.Glaxosmithkline Plc 8.3.2.1.Overview 8.3.2.2.Product Segments / End-User 8.3.2.3.Strategy 8.3.2.4.Key Developments 8.3.3.Aegerion Pharmaceuticals, Inc. (Novelion Therapeutics Inc.) 8.3.3.1.Overview 8.3.3.2.Product Segments / End-User 8.3.3.3.Strategy 8.3.3.4.Key Developments 8.3.4. Johnson & Johnson 8.3.4.1.Overview 8.3.4.2.Product Segments / End-User 8.3.4.3.Strategy 8.3.4.4.Key Developments 8.3.5.Thermo Fisher Scientific Inc. 8.3.5.1.Overview 8.3.5.2.Product Segments / End-User 8.3.5.3.Strategy 8.3.5.4.Key Developments 8.3.6. Novartis Ag 8.3.6.1.Overview 8.3.6.2.Product Segments / End-User 8.3.6.3.Strategy 8.3.6.4.Key Developments 8.3.7. Abbvie Inc. 8.3.7.1.Overview 8.3.7.2.Product Segments / End-User 8.3.7.3.Strategy 8.3.7.4.Key Developments 8.3.8.Celgene Corporation 8.3.8.1.Overview 8.3.8.2.Product Segments / End-User 8.3.8.3.Strategy 8.3.8.4.Key Development 8.3.9.Pfizer Inc 8.3.9.1.Overview 8.3.9.2.Product Segments / End-User 8.3.9.3.Strategy 8.3.9.4.Key Development LIST OF TABLES Table 1. Assumptions Table 2. Global Orphan Drugs Market Summary Table 3. Prevalence of Rare Diseases by Major Countries Table 4. List of Some of the Known Rare Diseases Table 5. Market Exclusivity for Orphan Drugs by Major Regions Table 6. Average Number of Patients in Clinical Trials Table 7. Market Attractiveness for Orphan Drugs Setup Table 8. Regulatory Analysis Snapshot Table 9. EMA Approved Orphan Drugs (2015 – 2016) Table 10. Orphan Drug Regulations in Other Countries Table 11. Time to Entry Analysis ( Standard Drugs vs. Orphan Drugs) Table 12. Average Time for FDA Approval Table 13. Orphan Drugs in Phase 3 Stage of the Development (2016) Table 14. Pricing with respect to prevalence of rare disease Table 15. Average Price of Orphan Drugs by Type Table 16. Pricing of Top Orphan Drugs with Average Market Price (2016) Table 17. List of 10 Top Marketed Orphan Drugs (2016) Table 18. Global Orphan Drugs Market Size (US$ billion), By Type (2016 – 2026) Table 19. Global Biological Orphan Drugs Market Size (US$ billion), By Regions (2016 – 2026) Table 20. Global Non-Biological Orphan Drugs Market Size (US$ billion), By Regions (2016 – 2026) Table 21. Global Orphan Drugs Market Size (US$ billion), By Therapeutic Area (2016 – 2026) Table 22. Global Orphan Drugs Market for Oncology; Market Size (US$ billion) (2016 – 2026) Table 23. Global Orphan Drugs Market for Neurology, Market Size (US$ billion) (2016 – 2026) Table 24. Global Orphan Drugs Market for Haematology, Market Size (US$ billion) (2016 – 2026) Table 25. Global Orphan Drugs Market for Infectious Disease, Market Size (US$ billion) (2016 – 2026) Table 26. Global Orphan Drugs Market for Metabolic Disease, Market Size (US$ billion) (2016 – 2026) Table 27. Global Orphan Drugs Market for Other Diseases, Market Size (US$ billion) (2016 – 2026) Table 28. Orphan Drugs Market Prospects, by Geography (2016 – 2026) Table 29. Global Orphan Drugs Market Size (US$ billion), By Geography (2016 – 2026) Table 30. Global Orphan Drugs Market, Market Size (%), By Major Regions (2016 – 2026) Table 31. Orphan Drugs Market in North America, Market Size (US$ billion) (2016 – 2026) Table 32. Orphan Drugs Market in U.S., Market Size (US$ billion), (2016 – 2026) Table 33. Orphan Drugs Market in Canada, Market Size (US$ billion), (2016 – 2026) Table 34. Orphan Drugs Market in North America, Market Size (US$ billion), By Type (2016 – 2026) Table 35. Orphan Drugs Market in North America, Market Size (US$ billion), By Therapeutic Area (2016 – 2026) Table 36. Orphan Drugs Market in Europe, Market Size (US$ billion) Table 37. Orphan Drugs Market in Germany, Market Size (US$ billion), (2016 – 2026) Table 38. Orphan Drugs Market in U.K, Market Size (US$ billion), (2016 – 2026) Table 39. Orphan Drugs Market in France, Market Size (US$ billion), (2016 – 2026) Table 40. Orphan Drugs Market in Italy, Market Size (US$ billion), (2016 – 2026) Table 41. Orphan Drugs Market in Rest of Europe, Market Size (US$ billion), (2016 – 2026) Table 42. Orphan Drugs Market in Europe, Market Size (US$ billion), By Type (2016 – 2026) Table 43. Orphan Drugs Market in Europe, Market Size (US$ billion), By Therapeutic Area (2016 – 2026) Table 44. Orphan Drugs Market in Asia-Pacific, Market Size (US$ billion) Table 45. Orphan Drugs Market in China, Market Size (US$ billion), (2016 – 2026) Table 46. Orphan Drugs Market in India, Market Size (US$ billion), (2016 – 2026) Table 47. Orphan Drugs Market in Australia, Market Size (US$ billion), (2016 – 2026) Table 48. Orphan Drugs Market in Japan, Market Size (US$ billion), (2016 – 2026) Table 49. Orphan Drugs Market in South Korea, Market Size (US$ billion), (2016 – 2026) Table 50. Orphan Drugs Market in Rest of Asia-Pacific, Market Size (US$ billion), (2016 – 2026) Table 51. Orphan Drugs Market in Asia-Pacific, Market Size (US$ billion), By Type (2016 – 2026) Table 52. Orphan Drugs Market in Asia-Pacific, Market Size (US$ billion), By Therapeutic Area (2016 – 2026) Table 53. Orphan Drugs Market in Rest of the World (ROW), Market Size (US$ billion) Table 54. Orphan Drugs Market in Latin America, Market Size (US$ billion), (2016 – 2026) Table 55. Orphan Drugs Market in Middle East & Africa, Market Size (US$ billion), (2016 – 2026) Table 56. Orphan Drugs Market in Rest of the World (ROW), Market Size (US$ billion), By Type (2016 – 2026) Table 57. Orphan Drugs Market in Rest of the World (ROW), Market Size (US$ billion), By Therapeutic Area (2016 – 2026) Table 58. Revenue from Orphan Drugs (US$ billion) By Major Players (2016 & 2016) Table 59. Orphan Drugs Market Snapshot Table 60. Acronyms LIST OF FIGURES Figure 1. Research Methodology Figure 2. Orphan Drugs Timeline Figure 3. Orphan Drugs by Stage of Development (2016) Figure 4. Orphan Drugs in Pipeline, by Therapeutic Area (2016) Figure 5. Global Orphan Drugs Market By Type: Market Size vs. Market Penetration (2016) Figure 6. Global Orphan Drugs Segment Share (%), By Type (2019-2026) Figure 7. Global Orphan Drugs Market Size (US$ billion), By Type (2019-2026) Figure 8. Global Biological Orphan Drugs Segment Share (%), By Regions (2019-2026) Figure 9. Global Biological Orphan Drugs Market Size (US$ billion), By Regions (2019-2026) Figure 10. Global Non-Biological Orphan Drugs Segment Share (%), By Regions (2019-2026) Figure 11. Global Non-Biological Orphan Drugs Market Size (US$ billion), By Regions (2019-2026) Figure 12. Market Attractiveness for Orphan Drugs, By Therapeutic (2016) Figure 13. Global Orphan Drugs Segment Share (%), By Therapeutic Area (2019-2026) Figure 14. Global Orphan Drugs Market Size (US$ billion), By Therapeutic Area (2019-2026) Figure 15. Global Orphan Drugs Market for Oncology, Market Size (US$ billion) (2019-2026) Figure 16. Global Orphan Drugs Market for Neurology, Market Size (US$ billion) (2015 & 2026) Figure 17. Global Orphan Drugs Market for Haematology, Market Size (US$ billion) (2019-2026) Figure 18. Global Orphan Drugs Market for Infectious Disease, Market Size (US$ billion) (2019-2026) Figure 19. Global Orphan Drugs Market for Metabolic Disease, Market Size (US$ billion) (2019-2026) Figure 20. Global Orphan Drugs Market for Other Diseases; Market Size (US$ billion) (2019-2026) Figure 21. Global Orphan Drugs Market, Segment Share (%), By Geography (2019-2026) Figure 22. Orphan Drugs Market in North America, Snapshot Figure 23. Orphan Drugs Market in North America, Market Size (US$ billion) (2019-2026) Figure 24. Orphan Drugs Market in North America, Segment Share (%) By Regions, (2019-2026) Figure 25. Orphan Drugs Market in North America, Market Size (US$ billion), By Type, 2016 &2026 Figure 26. Orphan Drugs Market in North America, Market Size (US$ billion), By Therapeutic Area (2019-2026) Figure 27. Orphan Drugs Market in Europe, Snapshot Figure 28. Orphan Drugs Market in Europe, Market Size (US$ billion) (2019-2026) Figure 29. Orphan Drugs Market in Europe, Segment Share (%) By Regions, (2019-2026) Figure 30. Orphan Drugs Market in Europe, Market Size (US$ billion), By Type (2019-2026) Figure 31. Orphan Drugs Market in Europe, Market Size (US$ billion), By Therapeutic Area (2019-2026) Figure 32. Orphan Drugs Market in Asia-Pacific, Snapshot Figure 33. Orphan Drugs Market in Asia-Pacific, Market Size (US$ billion) (2016 – 2026) Figure 34. Orphan Drugs Market in Asia-Pacific, Segment Share (%) By Regions, (2019-2026) Figure 35. Orphan Drugs Market in Asia-Pacific, Market Size (US$ billion), By Type (2019-2026) Figure 36. Orphan Drugs Market in Asia-Pacific, Market Size (US$ billion), By Therapeutic Area (2019-2026) Figure 37. Orphan Drugs Market in Rest of the World, Snapshot Figure 38. Orphan Drugs Market in Rest of the World, Market Size (US$ billion) (2016 – 2026) Figure 39. Orphan Drugs Market in Rest of the World, Segment Share (%) By Regions, (2019-2026) Figure 40. Orphan Drugs Market in Rest of the World, Market Size (US$ billion), By Type (2019-2026) Figure 41. Orphan Drugs Market in Rest of the World, Market Size (US$ billion), By Therapeutic Area (2019-2026) Figure 42. Market Share (%) of Major Players (2016) Figure 43. Market Positioning of Key Players

About This Report

Report ID342
Category Healthcare
Published DateNov 2019
No of Pages176
Contact Us
Call Now